This discussion summarizes the potential differences in physiologically and pharmacologically induced erections and highlights the possible differences in the pathways facilitated by oral versus intracavernosal agents in penile erection. Oral agents act in conjunction with sexual stimulation either increasing corporal smooth muscle relaxation or attenuating smooth muscle contraction. However, their ef®cacy is dependent on sexual stimulation. Intracavernosal administration of phosphodiesterase type 5 inhibitor (sildena®l) or short-acting alpha adrenergic receptor antagonist (phentolamine), in the absence of sexual stimulation, does not initiate penile erection. In contrast, intracavernosal administration of PGE1 or papaverine induces erection independent of sexual stimulation. Thus, oral agents are not direct mediators of smooth muscle relaxation and act to facilitate relaxation in response to sexual stimulation, while intracavernosal agents directly mediate smooth muscle relaxation, independent of sexual stimulation. Although, considerable advances have been made in elucidating the physiology and pharmacology of erectile function, details of the signal transduction pathways affected by these agents in the penile corpus cavernosum are yet to be fully investigated.
Introduction
A functional penile erection, with concomitant increase in cavernosal and helicine arterial in¯ow and activation of corporal veno-occlusion, ensues following either physiologic sexual stimulation or following intracavernosal administration of various vasorelaxatory agents. 1, 2 There are, however, signi®cant differences in the physiological and biochemical mechanisms of penile erection initiated by cavernosal nerve stimulation versus intracavernosal pharmacological agent administration. Furthermore, there are marked distinctions between the mechanism of action of erectogenic pharmacologic agents. 3, 4 For example, oral vasoactive agents administered to facilitate sexually stimulated erection (such as sildena®l as a phosphdiesterase type 5 inhibitor or phentolamine mesylate as an alpha-blocking agent) act via different mechanisms from pharmacologic intracavernosal agents which initiate erection without sexual stimulation (such as papaverine or PGE1). 3 Although basic and clinical research on the mechanisms of erection have provided new insights into the mode of action of pharmacological agents, limited data are available to explain the cellular and biochemical differences between physiologically and pharmacologically initiated erections.
The objective of this paper is to discuss the current state of knowledge of physiologically and pharmacologically induced erections and to highlight the possible differences between the nervestimulated versus the intracavernosal-mediated penile erection. This presentation is based on a series of questions and resultant discussions which occurred during the International Symposium on Alpha Blockade in Sexual Function, January 21±23, 1999 in San Juan, Puerto Rico. The discussions represent the integrated responses of many individual contributors present at this conference.
Physiology of penile erection following cavernosal nerve stimulation
In the experimental animal, cavernosal nerve stimulation results in an increase in arterial blood in¯ow to the cavernosal arteries, indicative of a decrease in vascular resistance of the helicine arterioles. 5 Subsequently, as a result of the expansion of the corpora and activation of the corporal veno-occlusive mechanism, a progressive increase in intracavernosal pressure is noted, reaching an equilibrium value approaching mean systemic arterial blood pressure. 5 The mechanism of cavernosal nerve-mediated activation of the corporal veno-occlusive mechanism can also be examined in the experimental animal model. 5, 6 In the absence of cavernosal nerve stimulation, corporal veno-occlusion does not develop. Intracavernosal infusion of saline at low ow rates (e.g. 1 ml/min) results in a small rise in intracavernosal pressure above baseline to a stable value, dependent in part on the magnitude of the saline infusion. Discontinuation of the saline infusion quickly results in intracavernosal pressure returning to baseline values. 6 Following cavernosal nerve stimulation, activation of corporal veno-occlusion is observed. Intracavernosal infusion of saline at low¯ow rates results in a marked rise in intracavernosal pressure. Termination of the saline infusion is associated with maintenance of the intracavernosal pressure. This marked difference between the intracavernosal pressure responses to saline infusion with and without cavernosal nerve stimulation is the result of physiologic activation of corporal veno-occlusion and development of corporal venous out¯ow resistance. 5, 6 Experimentally, the primary site of corporal veno-occlusion can be shown to occur within the sub-tunical venules. 7 Electron photomicrographs of penile casts in the¯accid and erect stale showed a stretching and¯attening of sub-tunical venules against the tunica albuginea. It is likely that another site of corporal venous out¯ow resistance occurs where the emissary veins, which drain through the tunica albugina, become compressed by the stretching of the circular and longitudinal layers of the tunica. 7 Other mechanisms may contribute to the increased venous out¯ow resistance following sexual stimulation and further research is required.
Following cavernosal nerve stimulation, several neurotransmitters are implicated in initiation of penile erection and alteration of the basal state of smooth muscle contractility of the cavernosal and helicine arteries and trabeculae. The exact nature of the endogenous neurotransmitters that initiate and/ or terminate penile erection remains under investigation. The non-adrenergic, non-cholinergic neurotransmitter nitric oxide (NO) plays a critical role in attenuating smooth muscle contraction and inducing smooth muscle relaxation and penile erection.
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. Activation of neurogenic and endothelial nitric oxide synthase results in synthesis of NO. Released NO diffuses into smooth muscle cells and binds to the heme component of soluble guanylyl cyclase, stimulating synthesis of cyclic guanosine monophosphate (cGMP). Binding of cGMP to cGMPdependent protein kinase (PKG) or cGMP dependent ion channels results in reduction of intracellular calcium, via calcium sequestration and extrusion, and activation of myosin light chain phosphatases causing diminution of smooth muscle contractility and enhancing penile erection.
Contractile agonists, such as norepinephrine, may modulate smooth muscle relaxation by binding to speci®c receptors in the endothelium. 11, 12 For instance, methoxamine, clonidine and B-HT 920 (agonists that stimulate contractility in smooth muscle) increase intracellular cGMP levels only in the presence but not in the absence of the endothelium, suggesting release of NO, presumably via activation of the alpha-2 adrenergic receptors on the endothelium. 11, 12 Microvascular constriction mediated by alpha-1 and alpha-2 adrenergic receptor activation is signi®cantly modulated by the endothelium, probably via activation of endothelial alpha-adrenergic receptors. 12 Activation of endothelial and/or neural nitric oxide synthase (NOS) and synthesis and release of NO physiologically antagonizes the action of smooth muscle alpha-adrenergic receptors at a point along the signal transduction pathway mediating smooth muscle tone. 13 In addition to activation of guanylyl cyclase, NO may activate K channels or Na /K ATPase which reduces intracellular calcium.
14 Furthermore, the endothelium releases other vasoactive substances such as prostaglandins, which activate speci®c Gs-protein-coupled receptors on the smooth muscle and increase cAMP synthesis. 15 The NO/cGMP signal transduction pathway, via protein kinase G (PKG), counteracts and overcomes the responses mediated by the signal transduction pathway of norepinephrine. 13 The latter pathway is mediated via alpha-1 and alpha-2 receptors and results in an increase in IP3 turnover and increased intracellular calcium. 16 The NOinduced shift in the balance towards reduced intracellular calcium results in enhanced relaxation. Increased intracellular levels of cAMP and cGMP result in activation of cGMP and cAMP-dependent protein kinases, activation of K channels and hyperpolarization. Hyperpolarization decreases Ca 2 in¯ux through L-type Ca 2 channels thus decreasing intracellular calcium and causing smooth muscle relaxation. 17 Since the alpha adrenergic pathway, together with other vasoconstrictors, exerts a dominant regulatory effect on trabecular smooth muscle tone, any physiological perturbations in this pathway, regardless of the nature of mediator, may have profound in¯uence on smooth muscle contractility. 18 An important concept to emphasize regarding the interaction of multiple and overlapping regulatory mechanisms is that no single pathway is completely inactive, at any given time, and is always operative at some basal level. This is illustrated by the ability of phosphodiesterase inhibitors to maintain adequate intracellular levels of cyclic nucleo-tides and induce relaxation in organ bath studies, in the absence of exogenously added nitric oxide or nerve stimulation. 19 Similarly, contraction is enhanced when basal release of NO synthesis is inhibited by arginine analogs (L-NMMA) in the presence of exogenous adrenergic agonists, suggesting that such pathways are always active at some basal level. 20 Therefore, it is important to appreciate the contributions of the contractile and vasodilator effector systems on smooth muscle contractility. This requires a comprehensive approach to understand the potential interactions (synergistic or antagonistic) of these vasodilator and vasoconstrictor systems in the physiology of erectile function.
Discussion of how systemically administered vasoactive agents may fascilitate`physiologic' cavernosal nerve-stimulated penile erection
Question 1
What is the mechanism by which an orally administered vasoactive agent facilitates sexually stimulated penile erection?
Discussion 1
Several vasoactive agents facilitate sexually stimulated smooth muscle relaxation such as phosphodiesterase type 5 inhibitors and alpha adrenergic receptor antagonists. 20, 21 These pharmacologic agents either increase corporal smooth muscle relaxation or attenuate smooth muscle contraction. These agents ultimately in¯uence changes in intracellular calcium and modulation of speci®c smooth muscle myosin light chain kinases (MLCK) and myosin light chain phosphatases (MLCP). These enzymes rapidly change the state of myosin phosphorylation and result in corporal smooth muscle contraction or relaxation.
20,21

Question 2
Speci®cally, how does an oral phosphodiesterase type 5 inhibitor facilitate sexually stimulated penile erection?
Discussion 2
Oral phosphodiesterase type 5 inhibitors act primarily to increase corporal smooth muscle relaxation. Following sexual stimulation and release of nitric oxide, intracellular cGMP concentrations are increased. Since intracellular cGMP levels are regulated by the action of cGMP speci®c phosphodiesterases, inhibitors of these enzymes will enhance corporal smooth muscle relaxation. 21 
Question 3
Speci®cally, how does an oral alpha adrenergic receptor antagonist facilitate sexually stimulated penile erection?
Discussion 3
Following sexual stimulation and release of NO, intracellular cGMP concentrations are increased which results in corporal smooth muscle relaxation. Since the corporal smooth muscle tone is regulated in part by the alpha adrenergic sympathetic pathway, alpha-blockers antagonize the activity of norepinephrine and attenuate the contractile response opposing the NO-mediated smooth muscle relaxation, thereby enhancing penile erection.
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Furthermore, since detumescence is mediated by alpha adrenergic agonist norepinephrine, blockade of the norepinephrine response and attenuation of smooth muscle contraction contributes to maintenance of penile erection. 22 
Question 4
Clinically, several oral alpha adrenergic receptor antagonists are available for treatment of benign prostatic hypertrophy and erectile dysfunction such as tamsulosin, doxazosin, terazosin, yohimbine, delequamine and phentolamine. Do these oral alpha adrenergic receptor antagonists facilitate the sexually stimulated penile erection with similar ef®cacy?
Discussion 4
There are several reasons why various alpha adrenergic receptor antagonists may possess varying ef®cacy in facilitating corpus cavernosum relaxation and enhancing penile erection. While the aforementioned compounds are competitive inhibitors of norepinephrine, albeit with varying degrees, these compounds belong to different classes of chemical compounds possessing different chemical constituents and therefore have different af®nities and selectivities to the alpha-1 and alpha-2 adrenergic receptor subtypes. 23 
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Effective inhibition of the alpha adrenergic receptor mediated physiological response requires that the antagonist be present in suf®cient concentration to compete for norepinephrine released from the adrenergic nerve in the synapse (mM range). When oral adrenergic blockers are given in doses ranging from 0.4 to 80 mg, it is expected that different plasma levels of such antagonists will be present. This may account, in part, for differences in activities. Also, the binding of these agents to plasma proteins may reduce the available free antagonist which can reach the receptor binding site. Further the duration of action and the clearance rates of the antagonist from plasma contributes to the alpha blocking activity and the observed response.
For all these reasons, the different alpha adrenergic receptor anatagonists are expected to display varying ef®cacy of activity and attenuation of the contractile response of penile erectile tissue.
Question 5
How would a speci®c oral alpha-1 adrenergic receptor antagonist (such as doxazosin or tamsulosin) act to facilitate sexually stimulated penile erection?
Discussion 5
A key aspect of the alpha adrenergic blockade is the selectivity of the oral alpha adrenergic receptor antagonist to the host of alpha receptor subtypes expressed on the smooth muscle of the corpus cavernosum and the cavernosal arteries and helicine arterioles. For example, tamsulosin is selective antagonist for alpha-1a and alpha-1d adrenergic receptor subtypes. 24 This narrow range of selectivity precludes tamsulosin binding to the alpha-2 receptor subtypes, leaving norepinephrine action at these receptors unopposed. 23 Thus only partial inhibition of the contractile response mediated by alpha-1 receptor antagonist is achieved. Another issue is the dose of the drug required to achieve complete alpha-1 receptor competitive antagonism in the corpora cavernosa during sexual stimulation. The dose required may be such that it is associated with adverse effects.
Question 6
How would a speci®c alpha-2 adrenergic receptor antagonist (such as yohimbine) act to facilitate sexually stimulated penile erection?
Discussion 6
The speci®c alpha-2 adrenergic receptor antagonist, yohimbine, is selective for the post-junctional and pre-junctional alpha-2 receptor subtypes. 25 Subsequent to administration of a pharmacological dose of yohimbine, one would expect the following events: (1) inhibition of the binding to post-junctional alpha-2 receptors on the corpus cavernosum smooth muscle attenuating contraction mediated by norepinephrine binding to the alpha-2 receptor; (2) inhibition of the pre-junctional alpha-2 receptors on the adrenergic nerve resulting in an increase in the release of norepinephrine, which binds to postjunctional alpha-1 adrenergic receptors and contributes to the contractile response; and (3) inhibition of the binding to pre-junctional alpha-2 receptors in the non-adrenergic, non-cholinergic nerves decreasing release of nitric oxide. The net peripheral effect of yohimbine may be to enhance contractility and may explain the limited clinical outcome with selective alpha-2 adrenergic blockade in patients with erectile dysfunction.
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Question 7
How would a speci®c alpha-1 and alpha-2 adrenergic receptor antagonist (such as phentolamine) act to facilitate the`physiologic' cavernosal nerve stimulated penile erection?
Discussion 7
Administration of pharmacological doses of alpha-1 and alpha-2 selective adrenergic receptor blocker would be expected to completely inhibit the action of norepinephrine post-junctionally. 20 The effect of pre-junctional alpha-2 receptor blockade on the adrenergic nerve and the noted increase in norepinephrine release is of little consequence since binding of released norepinephrine to the postjunctional alpha-1 receptors will be blocked by the antagonist. Because both alpha-1 and alpha-2 signal transduction pathways are effectively blocked by the antagonist, maximal attenuation of the contractile response is expected. Thus, optimal management of patients with erectile dysfunction using oral alpha adrenergic blockade would be to combine selective alpha-1 and alpha-2 adrenergic receptor antagonists. 20 
Question 8
Why is it that men who have undergone surgical removal of the sympathetic nerves (for example,
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T Lue et al during lymph node resection for testicular cancer) are not always experiencing priapistic episodes?
Discussion 8
The role of the alpha-adrenergic system in maintaining penile¯accidity remains controversial. It is likely that endogenously contractile agonists such as thromboxane, neuropeptide Y (NPY), PGF2 alpha, endothelin 27 and angiotensin also contribute to maintenance of penile¯accidity. The physiological response to these agents would likely remain unaffected by sympathectomy procedures. Alternative suggestions have been made as to the latchmechanism, in which the contractile response once achieved, is maintained with very limited contribution from the active mechanism of smooth muscle contractility. 28 The role of the alpha adrenergic system in detumescence is, however, non-controversial and well established. Oral adrenergic agonists, such as phenylpropanolamine have been well-recognized to diminish the duration of penile erections. 29 Surgical procedures, which theoretically result in complete sympathectomy leaving intact the parasympathetic pathways, may not result in initiation of penile erection unless associated with sexual stimulation.
Once the sexually stimulated erection was established, in the presence of complete sympathectomy, the erection duration may be prolonged. In experimental animals, 30 surgical or chemical sympathectomy did not result in priapism or any enhanced tumescence, in absence of nerve stimulation, but the erectile response to electrical stimulation was prolonged compared to control animals. 30 Furthermore, sexual complications in men who underwent bilateral lumbar sympathectomy were noted to be rare. 31 
Question 9
Why are some alpha adrenergic receptor antagonists associated with priapism (trazodone, prazosin) and some not (e.g. yohimbine)?
Discussion 9
An alpha adrenergic receptor antagonist which has high af®nity for the alpha adrenergic receptor coupled with a high concentration in the plasma for a longer duration would he expected to possess long-term alpha adrenergic blockade. Such agents would be expected to produce prolonged erection and priapism compared to agents with lower af®nity for the alpha receptor, which had lower plasma concentration and shorter duration of action. Thus, parasympathetic activity together with prolonged blockade of the symapthetic activity may promote cellular dysregulation of calcium homeostasis and produce priapism. 32, 33 Questions concerning intracavernosally administered vasoactive agents initiating pharmacological penile erection
Question 1
What are the hemodynamic responses observed upon administration of intracavernosal papaverine hydrochloride in the experimental animal model?
Discussion 1
Since the state of penile erection or¯accidity is, in large part, dependent upon the relaxation or contraction of the penile smooth muscles, both arterial and trabecular, various intracavernosally administered vasoactive agents may induce penile erection via different mechanisms. Administration of papaverine hydrochloride, intracavernosally, results in an increase in arterial blood¯ow into the corpora cavernosa. 5, 6, 34 In addition, effective activation of the corporal veno-occlusive mechanism is documented. In the experimental animal, saline infusion into the corporal bodies following intracavernosal papaverine results in intracavernosal pressure increases similar to that observed post-cavernosal nerve stimulation. In other words, intracavernosal pressure rises to a value approximating the mean systemic arterial blood pressure. 34 
Question 2
When one injects 60 mg of papaverine intravenously, the mean systemic arterial blood pressure decreases. When one injects 60 mg of papaverine intracavernosally, the blood pressure does not decrease. Why?
Discussion 2
Papaverine administered intracavernosally is associated with limited changes in the systemic mean arterial blood pressure. 33 This suggests papaverine activates the corporal veno-occlusive mechanism
Comparison of oral and intracavernosal vasoactive agents in penile erection T Lue et al and is maintained within the closed compartment system of the corpora cavernosa. However, administration of papaverine intravenously, affects smooth muscle cells of the blood vessels and is expected to cause vasodilation and changes in the systemic mean arterial blood pressure.
Question 3
What are the mechanisms by which intracavernosal papaverine hydrochloride induces corporal smooth muscle relaxation and erection?
Discussion 3
There have been few studies de®ning the mechanisms involved in papaverine-induced corporal smooth muscle relaxation. It is likely that papaverine is a multi-site acting drug, especially when utilized at high doses associated with intracavernosal therapy which exceed several hundred micromoles. Papaverine may act as: (1) non-speci®c phosphodiesterase inhibitor; (2) calcium channel blocker; and (3) activator of myosin light chain phosphatase. 17, 35 There have been recent studies indicating that the primary mechanism of papaverine is not mediated by phosphodiesterase inhibition since the concentration of papaverine needed to induce relaxation in the organ bath chamber far exceeds the inhibition constant of PDE type 5 (NN Kim et al, 1999, unpubished data). Similarly, the time course of relaxation induced by a dose of papaverine below its inhibition constant for PDE type 5 cannot be explained solely by phosphodiesterase inhibition. Thus papaverine may act as a calcium channel blocker or a phosphatase activator, however, more research on this topic is needed.
Question 4
Why is there a difference in the erectile response when NO is adminstered intracavernosally compared to the response observed following sexual stimulation (e.g cavernosal nerve stimulation?)
Discussion 4
Nitric oxide is a free radical agent with an approximate half-life of 4 s. Exogenously administered NO would be delivered in one location of the penile corpus cavernosum. Rapid inactivation during diffusion within the corpus cavernosum erectile tissue would be expected to occur. The limited intracellular cGMP produced in response to this single site injection would be effectively hydrolyzed by phosphodiesterases. Resultant partial smooth muscle relaxation would be predicted to induce a partial erection. In contrast the coordinated physiologic response results in NO release from the nerve and endothelium in multiple locations in the erectile tissue directly to the smooth muscle cell without exposure to hemoglobin which ef®ciently binds NO. Thus the erectile response via exogenous delivered NO may not mimic the physiologic response.
Question 5
What are the potential mechanisms by which the intracavernosal alpha adrenergic receptor antagonists induce penile erection?
Discussion 5
There is limited information regarding the alpha adrenergic system in erectile physiology and alpha blockers in the treatment of erectile dysfunction. At the sympathetic synapse with the corporal smooth muscle cell, the concentration of nerve-stimulated norepinephrine release is in the micromolar range, a relatively high concentration. Intracavernosal administration of an alpha blocker may or may not be adequate to counteract the local activity of norepinephrine. The concentration of alpha blockers necessary to compete with norepinephrine may vary over time depending on many factors, in particular, absorption, metabolism and lipid solubility of the alpha blocking agent. For example, phenoxybenzamine which has a long half-life ( b 20 h) may over time result in a penile erection following intracavernosal administration. In contrast, phentolamine has a short half-life (`3 h) and rarely results in a rigid penile erection following intracavernosal administration. Further, attenuation of the contractile response by alpha blockers may be insuf®cient to produce complete relaxation and functional erection. Intracavernosal injection of alpha blockers coupled with sexual stimulation may produce functional erection.
Question 6
What are the mechanisms by which the intracavernosal alpha-1 and alpha-2 adrenergic receptor antagonist, phentolamine, induce penile erection?
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Discussion 6
Repeating the saline infusion experiment with intracavernosal phentolamine resulted in increased arterial in¯ow but no activation of corporal venoocclusion. It was concluded that phentolamine increased only the arterial in¯ow without activating increases in venous out¯ow resistance. One explanation is there may be a central component associated with systemic administration of alpha adrenergic blockers that is not taken into account with intracavernosal administration. Another explanation may be that phentolamine may have more speci®c adrenergic blocking activity and ability to induce smooth muscle relaxation on the cavernosal and helicine artery smooth muscle compared to the trabecular smooth muscle. Another explanation may be the independent effect of sexual stimulation on the cavernosal artery and trabecular smooth muscle associated with oral administration compared to intracavernosal administration. Another explanation is that intracavernosal phentolamine has a very short half life and is cleared more rapidly. Approximately 5% remains as an authentic phentolamine and the rest is converted quickly to various metabolites. At least eight different metabolites have been identi®ed in human corpus cavernosum blood samples, post-injection of phentolamine. We do not know if such metabolites have any alpha blockade activity, but it may explain why intracavernosal phentolamine does not produce functional erection.
In in vivo studies, phentolamine is shown to dilate the cavernosal arteries. In organ bath studies, phentolamine causes relaxation of the trabecular smooth muscle. The cavernosal arteries may possess different densities of alpha receptor activity from that of the trabecular smooth muscle.
Another explanation may be the effect of dosedependency. What is the concentration of phentolamine which is suf®cient to produce complete alpha blockade? If one delivers small amounts of prostaglandin into the corpora cavernosal, (doses delivered transurethrally), one produces arterial dilation on color duplex ultrasonography, but not enough smooth muscle relaxation to produce venoocclusion and decrease in diastolic velocity. The amount of phentolamine utilized in the in vivo models may not be suf®cient to produce trabecular smooth muscle relaxation by complete alpha blockade.
It is important to realize that with intracavernosal injection the half-life of phentolamine is very short. So that the pharmacokinetics of the drugs are truly different between oral phentolamine versus intracavernosal phentolamine. The half life is signi®cantly different between intracavernosal injection and for orally administered phentolamine.
Question 7
What are the mechanisms by which the long acting intracavernosal alpha-1 adrenergic receptor antagonist phenoxybenzamine induce penile erection?
Discussion 7
Intracavernosal administration of phenoxybenzamine, a long acting alpha-adrenergic receptor antagonist, resulted in an increase in arterial in¯ow and after a protracted period of time activation of corporal veno-occlusion and a rigid penile erection.
The one caveat is that phenoxybenzamine, induces a long-acting pure alpha-blockade. Without associated sexual stimulation, phenoxybenzamine was able to achieve a slow developing penile erection, which ultimately achieved full rigidity. Since phenoxybenzamine, covalently binds (irreversible) to the alpha adrenergic receptor for protracted periods of time and cannot be displaced by norepinephrine, extended duration of alpha-blockade exists in the presence of phenoxybenzamine. Phenoxybenzamine (alpha-1 selective) induces penile erection without sexual stimulation, albeit with delayed duration (i.e may be an hour later) but apparently complete and irreversible blockade of the alpha adrenergic system produces functional erection in humans.
Conclusions
In penile erection, there are fundamental differences between the physiological pathways which are facilitated by currently available oral versus intracavernosal vasoactive agents. Oral agents act in conjunction with sexual stimulation either increasing corporal smooth muscle relaxation or attenuating smooth muscle contraction. Oral agents ultimately in¯uence changes in intracellular calcium but their ef®cacy is based on associated sexual stimulation. For example, intracavernosal administration of either phosphodiesterase type 5 inhibitors or short-acting alpha-adrenergic receptor antagonists, in the absence of sexual stimulation, will not initiate penile erection. In contrast, intracavernosal administration of PGE1 or papaverine induces erection independent of sexual stimulation. Oral agents such as sildena®l and phentolamine are not direct mediators of smooth muscle relaxation, where as intracavernosal agents such as papaverine and PGE1 are direct mediators of smooth muscle relaxation, independent of sexual stimulation.
